1
Interstitial Lung Diseases (ILD)Interstitial Lung Diseases (ILD)Diffuse Parenchymal Lung Diffuse Parenchymal Lung
Diseases (DPLD)Diseases (DPLD)Edit Csada, MDEdit Csada, MD
29.10.2014.29.10.2014.
1
2
Interstitial lung disorders Interstitial lung disorders (ILD)(ILD)
The interstitial lung disorders are The interstitial lung disorders are chronic, nonmalignant, chronic, nonmalignant, noninfectious diseases of the lower noninfectious diseases of the lower respiratory tract characterized by respiratory tract characterized by inflammation and derangement of inflammation and derangement of the alveolar walls.the alveolar walls.
Secondary fibrosis and pulmonal Secondary fibrosis and pulmonal hypertension may develophypertension may develop
Prevalence: 7-20/100 000Prevalence: 7-20/100 0002
3
Etiology (ATS/ERS 2002)
1. Known origin Drugs (busulfan,
nitrofurantoin, bleom., amiodaron)
Pneumoconiosis Connective tissue
diseases Irradiation Malignant diffuse
infiltr. lung diseases
2. Granulomatous origin
Sarcoidosis Hypersensitive
pneumonitis
4
Etiology
3. Other DPLD Langerhans-cell
histiocytosis Lymphangioleiomyo
matosis Alveolar proteinosis Wegener
granulomatosis
4. IIP UIP (IPF) DIP/RBILD NSIP AIP COP LIP
5
According to the pathogenesis I.
Acute DPLD allergy (drugs) toxin (gas) vasculitis/hemorrhage (Goodpasture,
idiopathic hemosiderosis) ARDS (trauma, septicaemia) unknown (COP, BOOP)
6
According to the pathogenesis II.
Episodic DPLD eo pneumonia vasculitis, hemorrhage Churg-Strauss sy Hypersensitive pneumonitis COP
7
According to the pathogenesis III.
Chronic DPLD (exposition)
inorganic dusts (silicosis, asbestosis) organic dusts (bacteria, fungi, animal
proteins) drugs
8
According to the pathogenesis IV.
Chronic DPLD (systemic diseases) sarcoidosis connective tissue diseases malignant diseases (lymphoma, lymphangitis cc) vasculitis (Wegener) hereditary diseases others ( bone marrow transplantation,
inflammatory intestine diseases, amyloidosis)
9
According to the pathogenesis V.
Chronic DPLD (without systemic disease and without exposition)
Idiopathic interstitial pneumonitis (IIP) alveolar proteinosis chronic aspiration LAM Langerhans-cell histiocytosis venoocclusive disease idiopathic pulmonal haemosiderosis bronchioloalveolar cc.
10
Morphologic changesMorphologic changes
Loss of pulmonary capillariesLoss of pulmonary capillaries Alterations of alveolar epithelial cellsAlterations of alveolar epithelial cells Fibrosis of alveolar wallsFibrosis of alveolar walls
PathogenesisPathogenesis
Total number of inflammatory cells increasesTotal number of inflammatory cells increases The proportions of inflammatory cells changeThe proportions of inflammatory cells change The inflammatory cells are activatedThe inflammatory cells are activated
Mediators release – toxic oxygen radical, proteasesMediators release – toxic oxygen radical, proteases FibrosisFibrosis Impairment of O2 transportImpairment of O2 transport
10
11
Normal cell content of BALNormal cell content of BAL
90%90% alveolar macrophagesalveolar macrophages 7%7% lymphocyteslymphocytes 1%1% polymorph leucocytespolymorph leucocytes
11
12
•Neutrophyl alveolitis : cryptogenic fibrotic alveolitis
•Lymfocytic alveolitis : sarcoidosis, hypersensitive pneumonitis, beryllosis
•Eosinophil alveolitis
•Mixed-cell alveolitis: amiodaron fibrosis (eosinophil+lymphocyte)
13
Clinical features in ILD I.Clinical features in ILD I.
SymptomsSymptoms Dyspnea during exerciseDyspnea during exercise FatigueFatigue Nonproductive coughNonproductive cough
Physical findingPhysical finding Dry, crackling ralesDry, crackling rales WheezingWheezing Tubular breath soundsTubular breath sounds Digital clubbingDigital clubbing
13
14
Clinical features in ILD II.Clinical features in ILD II.
Laboratory changesLaboratory changes ERS can be elevatedERS can be elevated HypoxaemiaHypoxaemia
Chest X-ray, HRCT scanChest X-ray, HRCT scan ReticularReticular NodularNodular ReticulonodularReticulonodular Ground glass hazinessGround glass haziness HoneycombingHoneycombing
14
15
Clinical features in ILD III.Clinical features in ILD III. Lung function testsLung function tests
Reduction in VC, TLCReduction in VC, TLC FEV1/FVC is normal, or supranormalFEV1/FVC is normal, or supranormal Decrease in diffusing capacity, transfer factorDecrease in diffusing capacity, transfer factor
(DLCO)(DLCO) Oxyergospirometry (exercise test)Oxyergospirometry (exercise test)
Scintigraphic findings Tc99, Xe133Scintigraphic findings Tc99, Xe133 Patchy abnormalitiesPatchy abnormalities
BALBAL Various mixtures of inflammatory cellsVarious mixtures of inflammatory cells
15
16
1717
1818
1919
2020
2121
22
Diagnosis of ILDDiagnosis of ILD
Clinical featuresClinical features Transbronchial biopsyTransbronchial biopsy VATSVATS Open lung biopsyOpen lung biopsy
22
23
Therapy of ILDTherapy of ILD Known etiologyKnown etiology
Remove the individual from exposure to the Remove the individual from exposure to the causative agentscausative agents
Known and unknown etiologyKnown and unknown etiology Suppress inflammatory processSuppress inflammatory process
Oral corticosteroids (1mg/kgOral corticosteroids (1mg/kg0,25 mg/kg)0,25 mg/kg) CPA (cyclophosphamide)CPA (cyclophosphamide) Imuran (azathioprine)Imuran (azathioprine)
Late stageLate stage O2 therapyO2 therapy Supportive treatmentSupportive treatment TransplantationTransplantation
23
24
Idioptahic pulmonary fibrosis Idioptahic pulmonary fibrosis (IPF)(IPF)
Hamman-Rich sy (acute IP)Hamman-Rich sy (acute IP) Cryptogenic fibrosing alveolitis (COP)Cryptogenic fibrosing alveolitis (COP) Desquamative intersitial pneumonitis Desquamative intersitial pneumonitis
(DIP)(DIP) Usual interstitial pneumonitis (UIP)Usual interstitial pneumonitis (UIP) Respiratory bronchiolytis-associted IP Respiratory bronchiolytis-associted IP
(RB-ILD)(RB-ILD) Nonspecific interstitial pneumonitis Nonspecific interstitial pneumonitis
(NSIP)(NSIP) Lymphoid interstitial pneumonitis (LIP)Lymphoid interstitial pneumonitis (LIP)
24
25
Idioptahic pulmonary fibrosis Idioptahic pulmonary fibrosis (IPF)(IPF)
The cause of condition is not clear.The cause of condition is not clear. Chr. inflammatory process initiated Chr. inflammatory process initiated
by immune complexesby immune complexes derangement of the lung derangement of the lung
parenchymaparenchyma The clinical features are similar to The clinical features are similar to
other ILDother ILD
25
26
Radiologic changes of IPFRadiologic changes of IPF
Ground glass hazinessGround glass haziness Streaky wisps of shadowStreaky wisps of shadow Generalized micronodular mottlingGeneralized micronodular mottling Honeycomb lungHoneycomb lung
26
27
Diagnosis of IPFDiagnosis of IPF
Clinical featuresClinical features X-rayX-ray CT scanCT scan Diffusing capacity, transfer factor Diffusing capacity, transfer factor
decreaseddecreased (DLCO) (DLCO) BAL (neutr.)BAL (neutr.) Transbronchial biopsyTransbronchial biopsy VATSVATS Open lung biopsyOpen lung biopsy
27
28
ATS/ERS ATS/ERS diagnostic criteria of IPF diagnostic criteria of IPF (biopsy)(biopsy)
Major Major criteriacriteria There is no known cause of ILD (drug, There is no known cause of ILD (drug,
environmental exposition) environmental exposition) Impaired lung function, restriction, decreased Impaired lung function, restriction, decreased
diffusion capacitydiffusion capacity Bilateral basal reticular, streaky shadow, Bilateral basal reticular, streaky shadow,
minimal granulomas minimal granulomas There is no other diseases with similar There is no other diseases with similar
symptomssymptoms Minor Minor criteriacriteria
AgeAge > 50 > 50 There is no other cause of dyspnoeThere is no other cause of dyspnoe Duration of diseaseDuration of disease > 3 > 3 monthmonth Bilateral basal subcrepitatioBilateral basal subcrepitatio AJRCCMAJRCCM
2002;165:277-3042002;165:277-304
29
Therapy of IPF (ATS) No treatment
Age > 70 years Extreme obesity DM, hearth disease, osteoporosis Severe impaired lung function Honeycomb lung
Early and combined treatment CS+ azathioprine CS+ cyclophosphamide CS+ azathioprine+ N-acetylcysteine
Restaging after 3-6-9-12-18 month Symptoms, radiology, lung function, side effects
PR, transplantation Best supportive care, O2 treatment
Therapy of IPF (ATS)
New drugsNew drugs InterferonInterferon BosentanBosentan EtanerceptEtanercept PirfenidonPirfenidon
30
31
Sarcoidosis (Morbus Boeck)Sarcoidosis (Morbus Boeck)
It is clinically well defined, systemic, It is clinically well defined, systemic, granulomatous disease of unknown granulomatous disease of unknown origin.origin.
HistologyHistology Altered immuneAltered immune
responseresponse
31
32
Clinical features of sarcoidosisClinical features of sarcoidosis
32
33
Radiological appearances of Radiological appearances of sarcoidosissarcoidosis
Stage/form IStage/form I BHL syBHL sy Stage/form IIStage/form II pulmonary pulmonary
dissemination dissemination with with or without BHLor without BHL
Stage/form IIIStage/form III pulmonary fibrosispulmonary fibrosis
33
3434
3535
3636
37
Diagnosis of sarcoidosisDiagnosis of sarcoidosis BHL accompanied by erythema nodosum BHL accompanied by erythema nodosum
(Löfgren-sy)(Löfgren-sy) Tuberculin test: negativeTuberculin test: negative Lung function testsLung function tests Se ACE (angiotensin converting enzyme) Se ACE (angiotensin converting enzyme)
increasesincreases Transbronchial biopsy, perbronchial biopsy Transbronchial biopsy, perbronchial biopsy
(TBNA)(TBNA) BAL (ly)BAL (ly) Gallium scanGallium scan MediastinoscopyMediastinoscopy
37
38
Treatment of sarcoidosisTreatment of sarcoidosis
Stage I:Stage I: no treatment is necessaryno treatment is necessary Indication of steroid treatment:Indication of steroid treatment:
Progressive pulmonary diseaseProgressive pulmonary disease Severe uveitisSevere uveitis HypercalcaemiaHypercalcaemia Neurological involvementNeurological involvement
38
39
Histiocytosis X (Langerhans)Histiocytosis X (Langerhans) This is a disorder of the mononuclear This is a disorder of the mononuclear
phagocyte system characterized by the phagocyte system characterized by the accumulation of mononuclear phagocytes accumulation of mononuclear phagocytes is various organs.is various organs.
In pediatric patientsIn pediatric patients Letterer-Siwe diseaseLetterer-Siwe disease Hand-Schüller-Christian diseaseHand-Schüller-Christian disease
In adultsIn adults Histiocytosis XHistiocytosis X Eosinophilic granulomaEosinophilic granuloma
39
40
Clinical features of Clinical features of histiocytosisXhistiocytosisX
20-40 years of age (smoking)20-40 years of age (smoking) Nonproductive coughNonproductive cough DyspneaDyspnea Chest painChest pain Ptx – 10% of all casesPtx – 10% of all cases
40
41
Characteristics of Characteristics of histiocytosisXhistiocytosisX X-ray changesX-ray changes
Reticulonodular shadowReticulonodular shadow Small cystic spacesSmall cystic spaces
Lung function testsLung function tests Mixed restrictive-obstructive patternMixed restrictive-obstructive pattern Decreased diffusing capacityDecreased diffusing capacity
BALBAL Large number of mononuclear phagocytesLarge number of mononuclear phagocytes
HistologyHistology X bodies (Birbeck) in the cytoplasmX bodies (Birbeck) in the cytoplasm
There is no known treatment. Corticosteroids may There is no known treatment. Corticosteroids may be given.be given.
41
42
Langerhans-cell histiocytosis
43
Rheumatoid arthritisRheumatoid arthritis
43
TreatmentTreatmentIf the disease is mild, no specific If the disease is mild, no specific therapy is used.therapy is used.If the ILD is progressive, corticosteroids If the ILD is progressive, corticosteroids are administered.are administered.
44
Other immunological Other immunological disesesdiseses
SLESLE Sjögren sySjögren sy SclerodermaScleroderma BechterewBechterew Dematomyositis, polymiositisDematomyositis, polymiositis Periarteritis nodosaPeriarteritis nodosa NeurofibromatosisNeurofibromatosis
44
45
Alveolar proteinosisAlveolar proteinosis
Primary-secondary (myeloid Primary-secondary (myeloid leukaemy, dust)leukaemy, dust)
PAS positive lipoproteinPAS positive lipoprotein X-ray: butterfly shape infiltrationX-ray: butterfly shape infiltration Therapy: BALTherapy: BAL
45
46
Eosinophylic pneumoniasEosinophylic pneumonias
The eosinophylic pneumonias are The eosinophylic pneumonias are characterized by eosinophilic characterized by eosinophilic pulmonary infiltrates and commonly pulmonary infiltrates and commonly peripherial blood eosinophylia.peripherial blood eosinophylia.
Known and unknown etiologyKnown and unknown etiology
46
47
Eosinophylic pneumoniasEosinophylic pneumonias Known etiologyKnown etiology
Allergic bronchopulmonary aspergillosis (ABPA)Allergic bronchopulmonary aspergillosis (ABPA) Parasitic infestations (ascaris, toxocara,etc)Parasitic infestations (ascaris, toxocara,etc) Drug reactions (nitrofurantoin, sulphonamides)Drug reactions (nitrofurantoin, sulphonamides)
Idiopathic (unknown etiology)Idiopathic (unknown etiology) Löffler’s syLöffler’s sy
Benign, acute eosinophilic pneumonia (AEP) with Benign, acute eosinophilic pneumonia (AEP) with migrating pulmonary infiltrates and minimal clinical migrating pulmonary infiltrates and minimal clinical manifestation.manifestation.
Chr. eosinophilic pneumonia (CEP)Chr. eosinophilic pneumonia (CEP) Symptoms: cough, sweats, fever, anorexia, weight loss, Symptoms: cough, sweats, fever, anorexia, weight loss,
chillschills X-ray: Peripherial infiltratesX-ray: Peripherial infiltrates
Allergic granulomatosis of Churg and StraussAllergic granulomatosis of Churg and Strauss Hypereosinophilic sy (HES)Hypereosinophilic sy (HES)
Therapy: corticosteroidsTherapy: corticosteroids
47
48
PNEUMOCONIOSIS
Etiologic agents: inhalation of inorganic dusts
metal dusts free silica coal dusts
49
HYPERSENSITIVE PNEUMONITIS(Extrinic allergic alveolitis)
It is an immunologically induced inflammation of lung parenchyma involving alveolar walls and terminal airways secondary to repeated inhalation of a variety of organic dusts and other agents by susceptible host.
Manifestations:Farmer’s lung (1932) – thermophylic actinomycetesBird fancier’s breeder’s or handler’s lung
Miller’s lungBagassosisByssinosis
Air conditioner’s lungCoffee worker’s lung
50Thank you for your attention!
Top Related